Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;39(4):545-553.
doi: 10.1016/j.det.2021.05.010. Epub 2021 Jun 1.

The Use of Biologics During the COVID-19 Pandemic

Madison E Jones  1 , Alison H Kucharik  2 , Sarah P Pourali  3 , Jeffrey R Rajkumar  4 , Yasmin Gutierrez  5 , Rebecca M Yim  1 , April W Armstrong  6
Affiliations
Review

The Use of Biologics During the COVID-19 Pandemic

Madison E Jones et al. Dermatol Clin. 2021 Oct.

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real-world evidence, and guidelines and recommendations for biologics that inhibit tumor necrosis factor, interleukin (IL)-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologics do not seem to increase the risk of COVID-19 infection or worsen COVID-19 outcomes. The impact of biologics on COVID-19 is an area of active exploration.

Keywords: Atopic dermatitis; Biologics; COVID-19; Dupilumab; Hidradenitis suppurativa; IL inhibitor; Psoriasis; TNF-Inhibitor.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr A.W. Armstrong has served as a research investigator and/or scientific advisor to AbbVie, BMS, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and Modmed. Madison Jones, Alison Kohn, Sarah Pourali, Jeffrey Rajkumar, Yasmin Gutierrez, and Rebecca Yim have nothing to disclose.

References

    1. Damiani G., Pacifico A., Bragazzi N.L., et al. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration. Dermatol Ther. 2020:e13475. - PMC - PubMed
    1. Schett G., Sticherling M., Neurath M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272. - PMC - PubMed
    1. Armstrong A.W., Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323(19):1945–1960. - PubMed
    1. Syed M.N., Shah M., Shin D.B., et al. Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;84(1):161–163. - PMC - PubMed
    1. Haberman R., Axelrad J., Chen A., et al. Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. 2020;383(1):85–88. - PMC - PubMed

MeSH terms

Substances